Matches in UGent Biblio for { <https://biblio.ugent.be/publication/4325555#aggregation> ?p ?o. }
Showing items 1 to 32 of
32
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B833649.
- aggregation creator B833650.
- aggregation creator B833651.
- aggregation creator B833652.
- aggregation creator person.
- aggregation date "2005".
- aggregation hasFormat 4325555.bibtex.
- aggregation hasFormat 4325555.csv.
- aggregation hasFormat 4325555.dc.
- aggregation hasFormat 4325555.didl.
- aggregation hasFormat 4325555.doc.
- aggregation hasFormat 4325555.json.
- aggregation hasFormat 4325555.mets.
- aggregation hasFormat 4325555.mods.
- aggregation hasFormat 4325555.rdf.
- aggregation hasFormat 4325555.ris.
- aggregation hasFormat 4325555.txt.
- aggregation hasFormat 4325555.xls.
- aggregation hasFormat 4325555.yaml.
- aggregation isPartOf urn:issn:0013-7006.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration".
- aggregation abstract "The single dose pharmacokinetic profiles of long-acting injectable (LAI) risperidone and oral risperidone were extrapolated to steady-state. Plasma concentrations of the active moiety (unchanged risperidone + 9-hydroxy-risperidone) were measured by radioimmunoassay up to 72 h after a single oral 1 mg dose of risperidone in healthy volunteers (n = 12), and up to 84 days after a single intramuscular injection of 50 mg LAI risperidone in schizophrenic patients (n = 26). These data were projected to multiple dose regimens (4 mg/day for the oral formulation and 50 mg every 2 weeks for LAI formulation) using the software package Win-Nonlin, and average steady-state pharmacokinetic profiles were predicted. The most interesting results, obtained at steady-state, were a lower predicted peak plasma level (46 vs. 62 ng/ml) and a lower predicted degree of fluctuation between c(ssmax) and C-ssmin,in (53 vs 145%) with LAI compared to oral administration, which is in line with actual steady state data on LAI risperidone. In conclusion, the pharmacokinetic profile of LAI risperidone administered every 2 weeks ensures a steady-state profile with concentrations falling in the interval observed with an equivalent oral dose but with lower and less fluctuations (i.e. 1/2 weeks vs 1/day).".
- aggregation authorList BK1208292.
- aggregation endPage "615".
- aggregation issue "5".
- aggregation startPage "609".
- aggregation volume "31".
- aggregation isDescribedBy 4325555.
- aggregation similarTo LU-4325555.